Because the role of immunoglobulins (IVIG) prophylaxis in patients undergoing hematopoietic stem-cell transplantation (HSCT) has not been established in terms of survival and infection prevention, we conducted a meta-analysis evaluating these issues.
INTRODUCTION
Patients undergoing hematopoietic stem-cell transplantation (HSCT; ie, bone marrow transplantation [BMT] or peripheral stem-cell transplantation [PSCT]), are highly susceptible to bacterial, fungal, and viral infections. [1] [2] [3] [4] [5] One approach advocated for prevention of infections is the administration of intravenous immunoglobulins (IVIG).
Favorable results of several randomized, controlled trials conducted before 2000 prompted the National Institutes of Health consensus panel to endorse the use of IVIG after allogeneic BMT.
2,5-12
Two meta-analyses in the early 1990s supported the use of IVIG in the context of BMT. 13, 14 However, since then more trials have been published with one major trial showing an increased risk for venoocclusive disease (VOD) with IVIG without a survival benefit. the American Society of Hematology and the annual Meeting of the European Hematology Association. The terms "immunoglobulins" or "gammaglobulins" or specific gammaglobulins and similar and the terms "hematologic neoplasms" or "hematologic malignancies" or "transplant" or "autotransplant" or "allotransplant" or "bone marrow transplant" or "peripheral stem-cell transplant" and similar were selected. We scanned references of all included trials and reviews identified for additional trials that did not come up in our search.
Study Selection
We included all randomized, controlled trials comparing the administration of intravenous or intramuscular polyvalent immunoglobulins (polyvalent IVIG) or hyperimmune cytomegalovirus-IVIG (CMV-IVIG) preparations with placebo, no treatment or another immunoglobulin preparation, a different administration schedule or dose for HSCT recipients. We included trials regardless of publication status, date of publication, and language. One author (P.R.) screened all references identified through our search strategy; two reviewers independently inspected each abstract and applied inclusion criteria. For possibly relevant articles or in the event of disagreement between the two reviewers, we obtained and independently inspected the full article.
Data Extraction and Quality Assessment
Two reviewers independently extracted data from included trials. In the event of disagreement between the two reviewers, a third reviewer extracted the data and results were attained by consensus. We contacted the authors of trials for missing data when necessary. We assessed allocation concealment, allocation generation, blinding, and intention-to-treat (ITT) analysis. We graded allocation concealment and generation as adequate, unclear, inadequate or not used using the criteria specified in the Cochrane handbook. 16 We used an individual component approach for quality assessment, since the use of composite scales has yielded conflicting results. 17 
Definition of Outcomes and Comparisons
The primary outcomes were all-cause mortality and clinically documented infections. Secondary outcomes included microbiologically documented bacterial infections, CMV infection, interstitial pneumonitis, acute GVHD, VOD, and adverse events. Mortality was extracted at 100 to 200 days and 1 to 2 years after HSCT.
We conducted the following comparisons: polyvalent IVIG versus placebo or no treatment; CMV-IVIG versus placebo or no treatment; polyvalent IVIG or CMV-IVIG versus placebo or no treatment; polyvalent IVIG versus CMV-IVIG; polyvalent IVIG at a dose of 250 mg/kg versus polyvalent IVIG at a dose of 500 mg/kg.
Data Synthesis and Analysis
For each trial, results were expressed as relative risks (RRs) with 95% CIs for dichotomous data (Review Manager [RevMan], version 4.2 for Windows; the Cochrane Collaboration, Oxford, United Kingdom). We conducted metaanalysis using a fixed-effect model. Outcomes were extracted preferentially by ITT analysis, including all individuals randomly assigned in the outcome assessment. However, when this was impossible, data were extracted perprotocol analyses. We assessed for heterogeneity in the results of the trials using a 2 test of heterogeneity (P Ͻ .1) and the I 2 measure of inconsistency. Subgroup analyses were conducted for type of transplantation (autologous v allogeneic) and the use of antifungal prophylaxis. We could not conduct separate subgroup analyses for type of graft (BMT v peripheral blood stem cell transplantation).
We searched for reasons for heterogeneity assessing the dose of IVIG used and type of HSCT (allogeneic or autologous). We performed sensitivity analyses to assess the effect of individual methodologic quality measures on effect estimates, including allocation generation, concealment, and blinding.
RESULTS
The computerized search strategy identified 855 trials, not all relevant for this review. Seventy-three trials were considered for this review, including eight abstracts from conference proceedings. Forty-three trials were excluded, including five reports identified as duplicate publications and considered under their primary reference (Fig 1) . Thirty trials performed between 1982 and 2003 and reporting on patients receiving IVIG after BMT (26 trials) or PSCT (two trials) or both (two trials) fulfilled inclusion criteria (Table 1) .
1-4, 6, 7, 9, 10, 12, 15, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Prophylaxis was initiated in most trials during conditioning (26 trials) or immediately after transplant (four trials) and was administered either weekly (16 trials), bi-weekly (eight trials), or by using a different schedule (six trials). In most trials prophylaxis was given for 3 months and the maximal period of administration was 1 year (Table 1) .
Polyvalent IVIG Versus Placebo or No Intervention (control)
Primary outcomes. Eight trials reported all-cause mortality, four reported at 100 to 200 days 15, 31, 35, 38 and four reported at 2 years and more.
2,4,5,27 There was no difference in the risk for all-cause mortality between polyvalent IVIG and control (RR, 0.99; 95% CI, 0.88 to 1.12), with no significant heterogeneity (P ϭ .4; I 2 ϭ 3.3%; Fig 2) . Analysis according to transplant type did not yield a difference in mortality between polyvalent IVIG and control, neither for the allogeneic transplant only group (RR, 1.07; 95% CI, 0.79 to 1.44) nor for the combined allogeneic and autologous transplant group (RR, 0.95; 95% CI, 0.81 to 1.10). In three trials that reported no antifungal prophylaxis the RR for mortality with IVIG was 0.88 (95% CI, 0.76 to 1.02), while in trials using antifungal prophylaxis the RR was 1.07 (95% CI, 0.74 to 1.53). There was no difference in all-cause mortality according to sensitivity analyses by randomization generation or blinding (Appendix Fig A1 online only) Polyvalent IVIG administration did not result in a decrease in the occurrence of clinically documented infections (RR, 1.00; 95% CI, 0.90 to 1.10; five trials). There was no evidence for heterogeneity in these comparisons (P ϭ .97; I 2 ϭ 0%; Fig 3) . 4,15,31,34,38 There was no difference in clinically documented infections between trials of adequate randomization generation (RR, 0.99; 95% CI, 0.86 to 1.14) and those in which randomization generation was not clear (RR, 1.00; 95% CI, 0.86 to 1.17). There was no difference in clinically documented infections between trials which were blinded (RR, 1.01; 95% CI, 0.91 to 1.12) and those not blinded (RR, 0.99; 95% CI, 0.86 to 1.15). When compared with control, polyvalent IVIG prophylaxis did not result in a decrease in the risk of acute GVHD (RR, 0.93; 95% CI, 0.83 to 1.04, seven trials), but resulted in a significantly increased risk for developing VOD (RR, 2.73; 95% CI, 1.11 to 6.71, four trials; Fig 4) .
When we separated the trials according to the type of transplant, there was an increased risk for VOD in both the allogeneic only group, RR 2.04 (95% CI 0.76-5.49, three trials) and the autologous only group (RR, 11.8; 95% CI, 0.66 to 210.03; one trial).
There was a significant increase in adverse effects in the polyvalent IVIG arm compared with control (RR, 8.12; 95% CI, 3.15 to 20.97; five trials). Adverse effects did not require discontinuation of treatment. They included mainly early adverse effects: fever, chills, nausea and vomiting, headache, myalgia, rash, and hypotension without anaphylaxis.
CMV-IVIG Versus Placebo or No Intervention (control)
Primary outcome. There was no difference in the risk for all-cause mortality (RR, 0.86; 95% CI, 0.63 to 1.16; four trials; Fig   2) , with no statistical evidence of heterogeneity (P ϭ .68; I 2 ϭ 0%). Mortality was assessed in these trials between 62 days 7 and 3 years after randomization.
18,21
When we combined the 12 trials assessing all-cause mortality with either polyvalent IVIG or CMV-IVIG as compared with control (Fig 2) , there was no difference in the risk for all-cause mortality (RR, 0.97; 95% CI, 0.87 to 1.09) and no statistical evidence of heterogeneity (P ϭ .54,; I 2 ϭ 0%). Secondary outcomes. Eight trials reported CMV infections and five trials reported interstitial pneumonitis. CMV-IVIG prophylaxis did not result in a decrease in the occurrence of CMV infections (RR, 1.02; 95% CI, 0.82 to 1.26, eight trials), with statistical evidence of heterogeneity (P ϭ .04; I 2 ϭ 53%) or interstitial pneumonitis (RR, 0.95; 95% CI, 0.58 to 1.56; five trials), with no statistical evidence of heterogeneity (P ϭ .27; I 2 ϭ 22.7%). CMV-IVIG administration did not result in a statistically significant decrease in the risk of infection-related death (RR, 0.67; 95% CI, 0.34 to 1.32; three trials), with no statistical evidence of heterogeneity (P ϭ .67; I 2 ϭ 0%) and acute GVHD compared with control (RR, 1.02; 95% CI, 0.72 to 1.44; five trials) with no statistical evidence of heterogeneity (P ϭ .88; I 2 ϭ 0%). Only one trial reported adverse effects for CMV-IVIG as compared with control with adverse effects occurring in the CMV-IVIG arm only (3 v none of 27 patients in each arm).
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Polyvalent IVIG Versus CMV-IVIG
When we compared polyvalent IVIG and CMV-IVIG, we found that all-cause mortality was higher with polyvalent IVIG without statistical significance (RR, 1.46; 95% CI, 0.92 to 2.32; three trials) with no significant heterogeneity (P ϭ .99; I 2 ϭ 0%). The risk for CMV infection, but not for interstitial pneumonitis, was higher with polyvalent IVIG prophylaxis than with CMV-IVIG prophylaxis (RR, 1.42; 95% CI, 1.07 to 1.89; three trials; v RR, 0.83; 95% CI, 0.40 to 1.75; two trials, respectively).
There was a higher rate of acute GVHD with polyvalent IVIG at a dose of 250 mg/kg as compared with 500 mg/kg (RR, 1.32; 95% CI, 1.13 to 1.55; three trials).
DISCUSSION
Our review shows that IVIG prophylaxis in patients undergoing HSCT, does not affect mortality or infection-related outcomes. It decreases the rate of interstitial pneumonitis and increases the risk for VOD.
Two meta-analyses have previously addressed IVIG treatment for patients undergoing BMT (Table 2) . 13, 14 Ours is the largest meta-analysis published so far and it supports the Glowaki et al conclusions regarding lack of effect on all cause mortality as well as the Bass et al conclusions regarding the other outcomes such as CMV infection, interstitial pneumonitis, and acute GVHD prophylaxis.
IVIG prophylaxis did not affect our primary outcome which was all cause mortality. This might be due to its lack of effect on clinically documented infections and acute GVHD, the major causes of early death in patients undergoing allogeneic HSCT. Furthermore, the beneficial effect of IVIG on interstitial pneumonitis was outweighed by its deleterious influence on VOD.
IVIG did not influence also our second primary outcome (ie, clinically documented infections). This might be due to the fact that causes for infections in patients who receive transplantation are multifactorial and consist also of causes other than hypogammaglobulinemia.
The most significant beneficial outcome in our study was the reduction of 36% in the occurrence of interstitial pneumonitis by polyvalent IVIG. Of note, our results favored treatment with IVIG only in the studies conducted, in the 1980s while the later studies, employing contemporary diagnostic and prophylactic strategies for CMV infections, actually favored control over IVIG (Fig 4) . Our data did not allow us to separate between CMV and non-CMV interstitial pneumonitis. Because both outcomes probably measure the same disease, the truer effect estimate for current practice is probably that of the newer studies.
An interesting finding in our meta-analysis was that polyvalent IVIG prophylaxis resulted in a significantly increased risk for developing hepatic VOD. Several possibilities might explain this disturbing increased risk. One explanation is an immunological insult to liver cells by IVIG which contain high levels of antibodies similar to the antibody gemtuzumab ozogamicin, which causes VOD through receptor mediated targeting of CD33 cells in the liver. Another mechanism suggested is through induction of hyperviscosity affecting the circulation in the small hepatic venules by IVIG. Alternatively, the effects of cytokines triggered by IVIG administration might also contribute to the development of VOD. 15 Therefore, our findings do not support the National Institutes of Health consensus recommendations for patients after BMT/HSCT.
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The compiled data available to date from randomized controlled trials does not demonstrate an improvement in mortality or morbidity with IVIG.
The main limitation of this review is that the majority of studies were old, with many of them reporting on patients treated in the 1980s and 1990s. In most studies, donors were HLA-matched siblings while the growing number of matched unrelated, haploidentical and cord blood transplants as well as the newer techniques of reduced intensity conditioning are not reflected in them.
In conclusion, lack of effect on mortality and lack of difference between the different preparations and doses of polyvalent IVIG do not support a true biologic effect of immunoglobulins in the context of BMT. These agents are associated with adverse effects, a higher rate of VOD, and are costly. Current evidence does not support their use as routine prophylaxis for patients undergoing BMT or HSCT. 
